PELP1 (RBT-PELP1), RMab

Summary and Explanation

A study has found that PELP1 antibody expression rate was the highest in breast cancers (70.5%) among different cancers. Compared to GATA3, Mammaglobin and GCDFP-15, PELP1 was less sensitive than GATA3 for luminal cancers, but was the most sensitive for non-luminal cancers. PELP1 has low expression rate (< 20%) in Colorectal Cancers, Gastric Cancers and Renal Cell Carcinomas, but higher in Lung Cancers (49.1%) and Ovarian Cancers (42.3%). PELP1 expression was associated with poor outcome in non-luminal cancers and modified the prognostic effects of AR, suggesting the potential significance of NR co-regulator in prognostication. Another study found the overall value of the PELP1 H-score in Breast cancer was significantly higher than that in breast fibroadenoma (p<0.001) with Breast Cancer patients, the ER/HER-2-positive group having significantly higher PELP1 H-scores than their negative counterparts (p=0.003 for ER and p=0.022 for HER-2) and the Ki-67-high group also showed significantly higher PELP1 H-scores than the Ki-67-low group.